A novel opioid compound that targets all three pain receptors in the
brain with no addiction potential was described this week at the CPDD
During the symposium “Next Generation Analgesics,” led by Dr. Nora
Volkow, director of the National Institutes on Drug Abuse (NIDA),
Lawrence Toll, Ph.D., co-founder and chief neuropharmacologist of
Phoenix PharmaLabs, described the drug. His talk “PPL-103: A kappa
partial agonist with potent antinociceptive activity and low abuse
potential” focused on the promising success that has been achieved in a
large number of published, as well as non-published, in vivo
studies to date.
All opioids on the market today bind to the mu receptor in the brain and
then aggressively stimulate that receptor. The mu receptor produces
euphoria that leads to abuse and addiction. PPL-103 is a patented analog
that binds strongly to all three opioid receptors in the brain (mu,
kappa and delta) and then partially stimulates those receptors in a more
balanced manner. This partial stimulation derives potent analgesic
benefit from all three receptors, but is not sufficiently strong to
produce the serious opioid side-effects associated with any single
receptor. This results in a first-ever opiate analgesic that appears to
be non-addicting and free of all significant dangerous side effects.
In vivo studies conducted to date have demonstrated that PPL-103
Phoenix PharmaLabs expects to file an IND to commence human clinical
trials in the coming 18 months.
Phoenix PharmaLabs (www.phoenixpharmalabs.com)
is a privately held, preclinical drug discovery company focused on the
development and commercialization of new potent, non-addictive
treatments for pain and new therapies for the treatment of addiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005141/en/